Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kodiak Sciences (KOD) EBITDA (2017 - 2026)

Kodiak Sciences filings provide 10 years of EBITDA readings, the most recent being -$59.8 million for Q1 2026.

  • Quarterly EBITDA fell 1.19% to -$59.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$235.1 million through Mar 2026, down 22.29% year-over-year, with the annual reading at -$230.0 million for FY2025, 30.51% down from the prior year.
  • EBITDA hit -$59.8 million in Q1 2026 for Kodiak Sciences, down from -$57.5 million in the prior quarter.
  • Across five years, EBITDA topped out at -$43.0 million in Q1 2024 and bottomed at -$95.7 million in Q1 2022.
  • Average EBITDA over 5 years is -$62.6 million, with a median of -$59.5 million recorded in 2023.
  • The largest annual shift saw EBITDA plummeted 89.59% in 2022 before it skyrocketed 43.67% in 2024.
  • Kodiak Sciences' EBITDA stood at -$69.2 million in 2022, then grew by 14.06% to -$59.5 million in 2023, then grew by 25.89% to -$44.1 million in 2024, then crashed by 30.26% to -$57.5 million in 2025, then fell by 4.05% to -$59.8 million in 2026.
  • Per Business Quant, the three most recent readings for KOD's EBITDA are -$59.8 million (Q1 2026), -$57.5 million (Q4 2025), and -$62.4 million (Q3 2025).